While genetic mouse models for some childhood cancers (e.g., MYCN-driven neuroblastoma) have been used to test agents that require an adaptive immune response, further research is required to develop robust panels of models across a diverse range of tumor types. The gene discussed is MYCN; the disease is neuroblastoma.